Cambridge, UK, 3 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, notes that partner Halozyme Therapeutics’ (“Halozyme”) has published an abstract for its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 on 2 April 2017.
The abstract outlines the significant preclinical anti-tumour activity of Halozyme’s HTI-1511 antibody drug conjugate (ADC), which uses Abzena’s novel, site specific ThioBridge™ linker technology. This will be presented in the poster ‘HTI-1511, a novel anti-EGFR-ADC, overcomes mutation resistance and demonstrates significant activity against multiple tumor types in preclinical studies’. The poster is jointly authored by scientists from Abzena, Halozyme and Champions Oncology Inc.
The abstract can be viewed online at: http://bit.ly/2mxFoTH The AACR Annual Meeting will be held at the Walter E. Washington Convention Center in Washington, D.C. from April 1 to April 5.
John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
|+44 1223 903 498
Melanie Toyne-Sewell / Rozi Morris/ Alex Shaw
|+44 20 7457 2020
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term “Abzena inside” is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on “Abzena inside” products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
- Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
- Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
- Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
- Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.
For more information, please see www.abzena.com